GPRC5D and plasma cell myeloma: T-cell bispecific antibodies (TCBs) have emerged as an effective therapeutic option in relapsed and refractory multiple myeloma, with G-coupled protein receptor, family C, group 5, member D (GPRC5D) representing a promising target due to its high expression in myeloma cells and limited presence in normal tissues.